Raymond Sanchez, MD

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

May 22, 2018

Finding effective treatment for depressed patients who do not adequately respond to antidepressant medications is a frequent challenge for clinicians. Read this article to learn about the efficacy, safety,...

Mary Hobart, Aleksandar Skuban, Peter Zhang, et al

Original Research

Aripiprazole to Treat Bipolar Disorder

March 29, 2017

Read a randomized control trial evaluating the efficacy and safety of once-monthly long-acting injectable antipsychotic aripiprazole.

Joseph R. Calabrese, Raymond Sanchez, Na Jin, et al

Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

Michael E. Thase, James M. Youakim, Aleksandar Skuban, et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

Michael E. Thase, James M. Youakim, Aleksandar Skuban, et al

Original Research

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

August 19, 2014

John M. Kane, Timothy Peters-Strickland, Ross A. Baker, et al

Original Research

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

May 15, 2012

John M. Kane, Raymond Sanchez, Pamela P. Perry, et al

Letter to the Editor

Reply to Aripiprazole and Perphenazine: No Difference

November 15, 2007

John M. Kane, Herbert Y. Meltzer, William H. Carson, Jr., et al

Original Research

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

October 15, 2007

Joseph R. Calabrese, Roger S. McIntyre, Robert D. McQuade, et al

Original Research

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

September 17, 2007

Gary S. Sachs, Bruce D. Gaulin, Rolando Gutierrez-Esteinou, et al

Original Research

Aripiprazole for Treatment-Resistant Schizophrenia: Results of a Multicenter, Randomized, Double-Blind, Comparison Study Versus Perphenazine

February 15, 2007

John M. Kane, Herbert Y. Meltzer, William H. Carson, Jr., et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled 26-Week Trial of Aripiprazole in Recently Manic Patients With Bipolar I Disorder.

April 15, 2006

Joseph R. Calabrese, Robert D. McQuade, William H. Carson, et al

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

Aripiprazole to Treat Bipolar Disorder

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Reply to Aripiprazole and Perphenazine: No Difference

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

Aripiprazole for Treatment-Resistant Schizophrenia: Results of a Multicenter, Randomized, Double-Blind, Comparison Study Versus Perphenazine

A Randomized, Double-Blind, Placebo-Controlled 26-Week Trial of Aripiprazole in Recently Manic Patients With Bipolar I Disorder.

ELSEWHERE:

FOLLOW US:

Raymond Sanchez, MD

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

Aripiprazole to Treat Bipolar Disorder

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Reply to Aripiprazole and Perphenazine: No Difference

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

Aripiprazole for Treatment-Resistant Schizophrenia: Results of a Multicenter, Randomized, Double-Blind, Comparison Study Versus Perphenazine

A Randomized, Double-Blind, Placebo-Controlled 26-Week Trial of Aripiprazole in Recently Manic Patients With Bipolar I Disorder.

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles